Regulation of cAMP by phosphodiesterases in erythrocytes.
Journal Title: Pharmacological Reports - Year 2010, Vol 62, Issue 3
Abstract
The erythrocyte, a cell responsible for carrying and delivering oxygen in the body, has often been regarded as simply a vehicle for the circulation of hemoglobin. However, it has become evident that this cell also participates in the regulation of vascular caliber in the microcirculation via release of the potent vasodilator, adenosine triphosphate (ATP). The regulated release of ATP from erythrocytes occurs via a defined signaling pathway and requires increases in cyclic 3',5'- adenosine monophosphate (cAMP). It is well recognized that cAMP is a critical second messenger in diverse signaling pathways. In all cells increases in cAMP are localized and regulated by the activity of phosphodiesterases (PDEs). In erythrocytes activation of either beta adrenergic receptors (beta(2)AR) or the prostacyclin receptor (IPR) results in increases in cAMP and ATP release. Receptor-mediated increases in cAMP are tightly regulated by distinct PDEs associated with each signaling pathway as shown by the finding that selective inhibitors of the PDEs localized to each pathway potentiate both increases in cAMP and ATP release. Here we review the profile of PDEs identified in erythrocytes, their association with specific signaling pathways and their role in the regulation of ATP release from these cells. Understanding the contribution of PDEs to the control of ATP release from erythrocytes identifies this cell as a potential target for the development of drugs for the treatment of vascular disease.
Authors and Affiliations
Shaquria Adderley, Randy Sprague, Alan Stephenson, Madelyn Hanson
Keywords
Related Articles
- EP ID EP144771
- DOI -
- Views 64
- Downloads 0
Contribution of the β-ureidopropionase (UPB1) gene alterations to the development of fluoropyrimidine-related toxicity.
Background: An impairment of the 5-fluorouracil (5-FU) catabolic pathway, represented by alterations in the dihydropyrimidine dehydrogenase (DPYD) gene, is considered a crucial factor contributing to the development of 5...
Effects of etoricoxib on the pharmacokinetics of phenytoin.
Etoricoxib is presently the most commonly prescribed cyclooxygenase-2 (Cox-2) inhibitor for chronic pain and inflammatory conditions. In clinical practice, phenytoin and etoricoxib are used in chronic conditions of gener...
Serotonin 2A receptor gene (HTR2A) polymorphism in alcohol-dependent patients.
Background: The serotonergic (5-HT) dysfunction has been frequently described in subjects with alcohol dependence (AD). In the present study, a potential relationship between T102C polymorphism in the 5-HT receptor subty...
Gender and the endothelium.
The understanding of the basis of gender differences in vascular function is of critical importance to establish gender targeted interventions in cardiovascular medicine. In this review we concentrate on the central role...
Large and micro coronary vascular involvement in diabetes.
Diabetes, with hyperglycemia as its hallmark, is a major risk factor forischemic heart disease. The role of coronary disease in the adverse prognosis of diabetes is controversial although the higher prevalence and extens...